Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: S ustained reductions in body weight, glycaemia and blood pressure over 1 year
Open accessAbstract
AIMS: Dapagliflozin and exenatide reduce body weight by differing mechanisms. Dual therapy with these agents reduces body weight, adipose tissue volume, glycaemia and systolic blood pressure (SBP) over 24 weeks. Here, we examined these effects over 1 year in obese adults without diabetes. MATERIALS AND METHODS: ) were initially randomized to double-blind oral dapagliflozin 10 mg once daily plus subcutaneous long-acting exenatide 2 mg once weekly or to placebo. They entered an open-label extension from 24 to 52 weeks during which all participants received active treatment. RESULTS: Of the original 25 dapagliflozin + exenatide-treated and 25 placebo-treated participants, respectively, 21 (84%) and 17 (68%) entered the open-label period and 16 (64%) and 17 (68%) completed 52 weeks of treatment. At baseline, mean body weight was 104.6 kg, and 73.5% of participants had prediabetes (impaired fasting glucose or impaired glucose tolerance). Reductions with dapagliflozin + exenatide at 24 weeks were sustained at 52 weeks, respectively, for body weight (-4.5 and -5.7 kg), total adipose tissue volume (-3.8 and -5.3 L), proportion with prediabetes (34.8% and 35.3%), and SBP (-9.8 and -12.0 mm Hg). Effects on body weight, SBP and glycaemia at 52 weeks with placebo → dapagliflozin + exenatide were similar to those observed with continuation of dapagliflozin + exenatide. Nausea and injection-site reactions were more frequent with dapagliflozin + exenatide than with placebo and diminished over time. Safety and tolerability were similar to that in previous diabetes trials with these agents. No clear difference in adverse event-related withdrawals between placebo and active treatment periods was observed. CONCLUSIONS: Dapagliflozin + exenatide dual therapy produced sustained reductions in body weight, prediabetes and SBP over 52 weeks and was well tolerated in obese adults without diabetes.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
SGLT-2 inhibitors combined with a GLP-1 agonist caused greater weight reduction than individual administration of each agent.
“Similarly, SGLT-2 inhibitors combined with a GLP-1 agonist caused a greater weight reduction than individual administration of each agent [105, 106].”
From Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand? (2021) · cites this paper as [105]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315 · see citing works
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · see citing works
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · see citing works
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724 · see citing works
Changes in Energy Expenditure Resulting from Altered Body Weight
Leibel, R. L., Rosenbaum, M., & Hirsch, J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503093321001 · Cited by 2,012 · see citing works
XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study
Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.155 · Cited by 1,915 · see citing works
Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline
Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, M. E., Murad, M. H., Pagotto, U., Ryan, D. H., & Still, C. D. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3415 · Cited by 1,347 · see citing works
Sjöström, L., Rissanen, A., Andersen, T., Boldrin, M., Golay, A., Koppeschaar, H. P., & Krempf, M. (1998) · The Lancet · doi:10.1016/s0140-6736(97)11509-4 · Cited by 1,237 · see citing works
Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163 · see citing works
Greenway, F. L., Fujioka, K., Plodkowski, R. A., Mudaliar, S., Guttadauria, M., Erickson, J., Kim, D. D., & Dunayevich, E. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60888-4 · Cited by 1,036 · see citing works
(2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00291-0 · Cited by 1,029 · see citing works
Davidson, M. H., Hauptman, J., DiGirolamo, M., Foreyt, J. P., Halsted, C. H., Heber, D., Heimburger, D. C., Lucas, C. P., Robbins, D. C., Chung, J., et al. (1999) · JAMA · doi:10.1001/jama.281.3.235 · Cited by 947 · see citing works
Multicenter, placebo-controlled trial of lorcaserin for weight management.
Smith, S. R., Weissman, N. J., Anderson, C. M., Sanchez, M., Chuang, E., Stubbe, S., Bays, H., & Shanahan, W. R. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909809 · Cited by 911 · see citing works
Khera, R., Murad, M. H., Chandar, A. K., Dulai, P. S., Wang, Z., Prokop, L. J., Loomba, R., Camilleri, M., & Singh, S. (2016) · JAMA · doi:10.1001/jama.2016.7602 · Cited by 865 · see citing works
Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
Lambers Heerspink, H. J., de Zeeuw, D., Wie, L., Leslie, B., & List, J. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12127 · Cited by 837 · see citing works
on behalf of the NN8022-1807 Investigators, Astrup, A., Carraro, R., Finer, N., Harper, A., Kunesova, M., Lean, M. E. J., Niskanen, L., Rasmussen, M. F., Rissanen, A., et al. (2012) · International Journal of Obesity · doi:10.1038/ijo.2011.158 · Cited by 757 · see citing works
Apovian, C. M., Aronne, L., Rubino, D., Still, C., Wyatt, H., Burns, C., Kim, D., Dunayevich, E., & for the COR‐II Study Group (2013) · Obesity · doi:10.1002/oby.20309 · Cited by 720 · see citing works
Allison, D. B., Gadde, K. M., Garvey, W. T., Peterson, C. A., Schwiers, M. L., Najarian, T., Tam, P. Y., Troupin, B., & Day, W. W. (2012) · Obesity · doi:10.1038/oby.2011.330 · Cited by 711 · see citing works
Food cue reactivity and craving predict eating and weight gain: A meta-analytic review
Boswell, R. G., & Kober, H. (2016) · Obesity Reviews · doi:10.1111/obr.12354 · Cited by 703 · see citing works
Mudaliar, S., Alloju, S., & Henry, R. R. (2016) · Diabetes Care · doi:10.2337/dc16-0542 · Cited by 571 · see citing works
Fidler, M. C., Sanchez, M., Raether, B., Weissman, N. J., Smith, S. R., Shanahan, W. R., & Anderson, C. M. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1256 · Cited by 561 · see citing works
Wadden, T. A., Foreyt, J. P., Foster, G. D., Hill, J. O., Klein, S., O'Neil, P. M., Perri, M. G., Pi‐Sunyer, F. X., Rock, C. L., Erickson, J. S., et al. (2011) · Obesity · doi:10.1038/oby.2010.147 · Cited by 558 · see citing works
Johns, D. J., Hartmann‐Boyce, J., Jebb, S. A., & Aveyard, P. N. (2014) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2014.07.005 · Cited by 522 · see citing works
Bolinder, J., Ljunggren, Ö., Johansson, L. O. M., Wilding, J. P. H., Langkilde, A., Sjöström, C. D., Sugg, J. E., & Parikh, S. J. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12189 · Cited by 484 · see citing works
Self-citationRössner, S., Sjöström, L., Noack, R., Meinders, A. E., Noseda, G., & Study, O. B. O. T. E. O. O. (2000) · Obesity Research · doi:10.1038/oby.2000.8 · Cited by 476 · see citing works
Wu, J. H. Y., Foote, C., Blomster, J., Toyama, T., Perkovic, V., Sundström, J., & Neal, B. C. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)00052-8 · Cited by 471 · see citing works
Frías, J. P., Guja, C., Hardy, E., Ahmed, A., Dong, F., Öhman, P., & Jabbour, S. A. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30267-4 · Cited by 399 · see citing works
Orlistat in the long-term treatment of obesity in primary care settings.
Hauptman, J. (2000) · Archives of Family Medicine · doi:10.1001/archfami.9.2.160 · Cited by 367 · see citing works
Energy Balance After Sodium–Glucose Cotransporter 2 Inhibition
Ferrannini, G., Hach, T., Crowe, S., Sanghvi, A., Hall, K. D., & Ferrannini, E. (2015) · Diabetes Care · doi:10.2337/dc15-0355 · Cited by 362 · see citing works
Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS
van Bloemendaal, L., ten Kulve, J. S., la Fleur, S. E., Ijzerman, R. G., & Diamant, M. (2014) · Journal of Endocrinology · doi:10.1530/joe-13-0414 · Cited by 312 · see citing works
Wilding, J. P. H., Woo, V. C., Rohwedder, K., Sugg, J. E., Parikh, S. J., & for the Dapagliflozin 006 Study Group (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12187 · Cited by 293 · see citing works
Kasichayanula, S., Liu, X., LaCreta, F., Griffen, S. C., & Boulton, D. W. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0104-3 · Cited by 276 · see citing works
Prato, S. D., Nauck, M. A., Durán-Garcia, S., MAFFEI, L. E., Rohwedder, K., Theuerkauf, A., & Parikh, S. J. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12459 · Cited by 232 · see citing works
Sonesson, C., Johansson, P. A., JOHNSSON, E. K., & Gause‐Nilsson, I. A. M. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0356-y · Cited by 175 · see citing works
Self-citationMonami, M., Dicembrini, I., Nardini, C., Fiordelli, I., & Mannucci, E. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12175 · Cited by 174 · see citing works
Evolution of pharmacological obesity treatments: focus on adverse side‐effect profiles
Krentz, A. J., Fujioka, K., & Hompesch, M. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12657 · Cited by 168 · see citing works
Canagliflozin: effects in overweight and obese subjects without diabetes mellitus
Bays, H. E., Weinstein, R., Law, G., & Canovatchel, W. (2014) · Obesity · doi:10.1002/oby.20663 · Cited by 166 · see citing works
Bailey, C. J., Villegas, E. C. M., Woo, V. C., Tang, W., Ptaszynska, A., & List, J. F. (2014) · Diabetic Medicine · doi:10.1111/dme.12624 · Cited by 153 · see citing works
Diamant, M., Gaal, L. V., Guerci, B., Stranks, S. N., Han, J., Malloy, J. L., Boardman, M. K., & TRAUTMANN, M. E. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70029-4 · Cited by 152 · see citing works
Hartmann‐Boyce, J., Johns, D. J., Jebb, S. A., Summerbell, C. D., Aveyard, P. N., & Behavioural Weight Management Review Group (2014) · Obesity Reviews · doi:10.1111/obr.12220 · Cited by 149 · see citing works
Rajasekeran, H., Lytvyn, Y., & Cherney, D. Z. I. (2016) · Kidney International · doi:10.1016/j.kint.2015.12.038 · Cited by 129 · see citing works
Ptaszynska, A., Johnsson, K. M., Parikh, S. J., de Bruin, T. W., Apanovitch, A. M., & List, J. F. (2014) · Drug Safety · doi:10.1007/s40264-014-0213-4 · Cited by 123 · see citing works
Lundkvist, P., Sjöström, C. D., Amini, S., Pereira, M. J., Johnsson, E., & Eriksson, J. W. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12779 · Cited by 108 · see citing works
Self-citationRationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial
Holman, R. R., Bethel, M. A., George, J. T., Sourij, H., Doran, Z., Keenan, J. F., Khurmi, N. S., Mentz, R. J., Oulhaj, A., Buse, J. B., et al. (2015) · American Heart Journal · doi:10.1016/j.ahj.2015.12.009 · Cited by 105 · see citing works
Broom, J. I., Wilding, J. P. H., Stott, P., Myers, N., & UK Multimorhidity Study Group (2002) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2002.tb11307.x · Cited by 103 · see citing works
Weight reduction and long-term maintenance after 18 months treatment with orlistat for obesity
Krempf, M., Jp, L., Allanic, H., Miloradovich, T., Joubert, J., & Attali, J. (2003) · International Journal of Obesity · doi:10.1038/sj.ijo.0802281 · Cited by 89 · see citing works
Dhurandhar, E. J., Kaiser, K. A., Dawson, J. A., Alcorn, A., Keating, K. D., & Allison, D. B. (2014) · International Journal of Obesity · doi:10.1038/ijo.2014.184 · Cited by 88 · see citing works
Irace, C., Luca, S. D., Shehaj, E., Carallo, C., Loprete, A., Scavelli, F. B., & Gnasso, A. (2012) · Diabetes and Vascular Disease Research · doi:10.1177/1479164112449562 · Cited by 72 · see citing works
Zhang, F., Tong, Y., Su, N., Li, Y., Tang, L., Huang, L., & Tong, N. (2015) · Journal of Diabetes · doi:10.1111/1753-0407.12198 · Cited by 59 · see citing works
Investigation of the haemodynamic effects of exenatide in healthy male subjects
Mendis, B., Simpson, E., MacDonald, I., & Mansell, P. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04214.x · Cited by 56 · see citing works
Five-Year Efficacy and Safety Data of Exenatide Once Weekly
Wysham, C., MacConell, L., Maggs, D. G., Zhou, M., Griffin, P. S., & TRAUTMANN, M. E. (2015) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2015.01.008 · Cited by 52 · see citing works
Henry, R. R., KLEIN, E. J., Han, J., & Iqbal, N. (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0107 · Cited by 45 · see citing works
Liu‐Seifert, H., Andersen, S. W., Lipkovich, I. A., Holdridge, K. C., & Siemers, E. (2015) · PLoS ONE · doi:10.1371/journal.pone.0119632 · Cited by 44 · see citing works
Combinations of drugs in the Treatment of Obesity
Halpern, B., Oliveira, E. S. L., Faria, A. M., Halpern, A., de Melo, M. E., Cercato, C., & Mancini, M. C. (2010) · Pharmaceuticals · doi:10.3390/ph3082398 · Cited by 36 · see citing works
SGLT2 inhibitors: β blockers for the kidney?
Gilbert, R. E. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30237-6 · Cited by 35 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?
Tak, Y. J., & Lee, S. Y. (2021) · Current Obesity Reports · doi:10.1007/s13679-020-00422-w · Cited by 343 · see citing works
Sargeant, J. A., Henson, J., King, J. A., Yates, T., Khunti, K., & Davies, M. J. (2019) · Endocrinology and Metabolism · doi:10.3803/enm.2019.34.3.247 · Cited by 231 · see citing works
Ikonomidis, I., Pavlidis, G., Thymis, J., Birba, D., Kalogeris, A., Kousathana, F., Kountouri, A., Balampanis, K., Parissis, J., Andreadou, I., et al. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.015716 · Cited by 199 · see citing works
Drug therapy in obesity: a review of current and emerging treatments
Williams, D. M., Nawaz, A., & Evans, M. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00816-y · Cited by 195 · see citing works
Lee, P. C., Ganguly, S., & Goh, S. ‐. (2018) · Obesity Reviews · doi:10.1111/obr.12755 · Cited by 189 · see citing works
Ismaiel, A., Scarlata, G. G. M., Boitos, I., Leucuta, D.-C., Popa, S.-L., Al Srouji, N., Abenavoli, L., & Dumitrascu, D. L. (2025) · International Journal of Obesity · doi:10.1038/s41366-025-01859-6 · Cited by 99 · see citing works
Jabbour, S. A., Frías, J. P., Ahmed, A., Hardy, E., Choi, J., Sjöström, C. D., & Guja, C. (2020) · Diabetes Care · doi:10.2337/dc19-1350 · Cited by 69 · see citing works
Self-citationZheng, H., Liu, M., Li, S., Shi, Q., Zhang, S., Zhou, Y., & Su, N. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.706914 · Cited by 60 · see citing works
Combination therapies for obesity
Camilleri, M., & Acosta, A. (2018) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2018.0075 · Cited by 59 · see citing works
- Authors
- Lundkvist, P., Pereira, M. J., Katsogiannos, P., Sjöström, C. D., Johnsson, E., & Eriksson, J. W.
- Affiliations
- Uppsala University (SE)
- AstraZeneca (Sweden) (SE)
- Corresponding author
- Eriksson, Jan W.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2017-05-31
- Volume
- 19
- Issue
- 9
- Pages
- 1276-1288
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- PMC
- PMC5575470
- OpenAlex
- W2602313931
- Cited by
- 72
- References
- 55
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 12 · 2023: 9 · 2022: 7 · 2021: 10 · 2020: 13 · 2019: 4 · 2018: 6 · 2017: 3
- FWCI
- 5.62
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Obesity and Metabolism (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- KTH Publication Database DiVA (KTH Royal Institute of Technology) (submittedVersion, other-oa)
- Funders
- Sanofi
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Epidemiology › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- dapagliflozin, exenatide, obesity, prediabetes, weight loss, adipose tissue volume, systolic blood pressure, glycemia, dual therapy, sustained weight loss, nausea, injection site reactions, open-label extension
- MeSH terms
- Proof of Concept Study, Exenatide, Benzhydryl Compounds, Cardiovascular Diseases, Double-Blind Method, Drug Administration Schedule, Drug Therapy, Combination, Female, Follow-Up Studies, Glucosides, Humans, Hypoglycemic Agents, Male, Middle Aged, Obesity, Peptides, Prediabetic State, Risk Factors, Sweden, Venoms, Weight Loss, Body Mass Index, Anti-Obesity Agents, Membrane Transport Modulators, Adiposity, Sodium-Glucose Transport Proteins, Ghrelin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
